Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR-T Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Biomaterials Science
• Synthetic Biology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy shows promise in cancer treatment but faces limitations in solid tumors.
• Challenges include toxicity, immune resistance, poor T cell infiltration into the tumor microenvironment (TME), and T cell exhaustion.

Purpose of the Study:

• To review innovative strategies using synthetic biology and biomaterials to enhance CAR-T cell efficacy in solid tumors.
• To explore how biomaterials can address challenges like TME barriers and off-tumor toxicity.
• To discuss future directions in engineering advanced CAR-T cell therapies.

Main Methods:

• Review of recent advances in synthetic biology and biomaterial applications for CAR-T cell engineering.
• Analysis of biomaterials as delivery vehicles, artificial antigen-presenting cells (APCs), screening platforms, and TME simulators.
• Exploration of synthetic circuits for improved CAR-T cell function and safety.

Main Results:

• Biomaterials offer novel approaches to engineer more responsive and effective CAR-T cells.
• Applications include precision delivery, mimicking the TME, and enhancing T cell infiltration and function.
• Synthetic biology enables the creation of sophisticated CAR-T cells with built-in safety mechanisms.

Conclusions:

• Biomaterials and synthetic biology are crucial for advancing CAR-T cell immunotherapy against solid tumors.
• These interdisciplinary approaches hold the potential to overcome current limitations and minimize adverse effects.
• Future research focusing on tumor-inspired biomaterials and advanced T cell engineering will lead to next-generation CAR-T therapies.